Dyadic International Inc. is a global biotechnology company that develops and commercializes gene expression platforms for producing high-value proteins and industrial enzymes. The company's proprietary C1 technology, based on the Thermothelomyces heterothallica fungus, enables the large-scale production of strategic input proteins for non-pharmaceutical applications. These proteins serve as essential components across the life sciences, food and nutrition, and bioindustrial sectors, supporting bioprocessing, formulation, and product development. By focusing on non-pharmaceutical applications, Dyadic International helps customers avoid the regulatory complexity and substantial costs associated with therapeutic biologics. The company has licensed its technology to major industry partners including BASF, Codexis, and Abengoa Bioenergy for use in industrial applications. Founded in 1979 and headquartered in Jupiter, Florida, Dyadic International operates as a platform provider enabling innovation across multiple high-growth markets.